While there are now a slew of approved, effective vaccines that curb COVID-19 infections, there is only one FDA-approved therapeutic to fight ongoing COVID-19 infection: remdesivir. This relative lack of medications for COVID-19 patients has left researchers hunting for alternatives, ideally from known pharmaceutical compounds for easy deployment. Now, researchers at the San Diego Supercomputer Center (SDSC) are using HPC to continue the hunt – specifically, through one of SARS-CoV-2’s key proteins.
The post San Diego Supercomputers Investigate Drug Repurposing for COVID-19 appeared first on HPCwire.
